Search Result

Results for "

eosinophils

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (3) Apoptosis (7) CCR (1) Cytochrome P450 (1) Drug Metabolite (1) E1/E2/E3 Enzyme (1) Endogenous Metabolite (3) Glucocorticoid Receptor (3) HDAC (3) Histamine Receptor (13) IKK (1) Integrin (2) Interleukin Related (10) Isotope-Labeled Compounds (2) JAK (1) Leukotriene Receptor (4) Lipoxygenase (1) mAChR (1) Neurotensin Receptor (2) NF-κB (1) PAK (2) Phosphodiesterase (PDE) (5) Platelet-activating Factor Receptor (PAFR) (1) Prostaglandin Receptor (3) STAT (2) TNF Receptor (3)
By Research Areas:	Cancer (9) Cardiovascular Disease (3) Endocrinology (7) Infection (1) Inflammation/Immunology (40) Metabolic Disease (1) Neurological Disease (4)

By Targets:

Adenosine Receptor (3)

Apoptosis (7)

CCR (1)

Cytochrome P450 (1)

Drug Metabolite (1)

E1/E2/E3 Enzyme (1)

Endogenous Metabolite (3)

Glucocorticoid Receptor (3)

HDAC (3)

Histamine Receptor (13)

IKK (1)

Integrin (2)

Interleukin Related (10)

Isotope-Labeled Compounds (2)

JAK (1)

Leukotriene Receptor (4)

Lipoxygenase (1)

mAChR (1)

Neurotensin Receptor (2)

NF-κB (1)

PAK (2)

Phosphodiesterase (PDE) (5)

Platelet-activating Factor Receptor (PAFR) (1)

Prostaglandin Receptor (3)

STAT (2)

TNF Receptor (3)

By Research Areas:

Cancer (9)

Cardiovascular Disease (3)

Endocrinology (7)

Infection (1)

Inflammation/Immunology (40)

Metabolic Disease (1)

Neurological Disease (4)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W105101

3,5-Dibromotyrosine

Others Others

3,5-Dibromotyrosine is a product of protein oxidation by eosinophil peroxidase .

3,5-Dibromotyrosine	Others	Others
3,5-Dibromotyrosine is a product of protein oxidation by eosinophil peroxidase .

HY-106215

Etiprednol dicloacetate BNP 166; Etiprednol dichloroacetate	Others	Inflammation/Immunology
Etiprednol dicloacetate (BNP 166) is an anti-inflammatory agent. Etiprednol dicloacetate inhibits eosinophil accumulation. Etiprednol dicloacetate can be used in the research of inflammatory airway diseases, such as asthma .

HY-120629

BMS-639623	CCR	Inflammation/Immunology
BMS-639623 is a potent and orally activeCCR3 antagonist with an IC₅₀ of 0.3 nM. BMS-639623 picomolar inhibition potency against eosinophil chemotaxis (IC₅₀=38 pM). BMS-639623 can be used for the research of asthma .

HY-137308

15(R)-Prostaglandin D2 15R-PGD2	Prostaglandin Receptor	Inflammation/Immunology
15(R)-Prostaglandin D2 is a potential prostatic hormone DP(2) receptor (Prostaglandin Receptor) agonist with anti-inflammatory activity. 15(R)-Prostaglandin D2 increases actin polymerization in human eosinophils and increases cAMP levels in platelets .

HY-P99846

Dectrekumab QAX576	Interleukin Related	Inflammation/Immunology
Dectrekumab (QAX576) is a human monoclonal antibody that targets IL-13. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research .

HY-101173

Imetit dihydrobromide VUF 8325 dihydrobromide; SKF 91105 dihydrobromide	Histamine Receptor	Neurological Disease
Imetit dihydrobromide (VUF 8325 dihydrobromide) is a high affinity and potent agonist of histamine H3 and H4 receptors, with K_i values of 0.3 and 2.7 nM, respectively. Imetit mimics histamine effect in triggering a shape change in eosinophils (EC₅₀=25 nM) .

HY-155819

M3/PDE4 modulator-1	mAChR Phosphodiesterase (PDE)	Inflammation/Immunology
M3/PDE4 modulator-1 (compound 10f) is a bifunctional molecule that is an M3 mAChR antagonist and a PDE4 inhibitor. M3/PDE4 modulator-1 (10-1000 nM/kg; iv) reduces cysteine eosinophil influx in the OVA rat model .

HY-B1121

Flunisolide 1 Publications Verification	Glucocorticoid Receptor Apoptosis	Inflammation/Immunology Endocrinology
Flunisolide is a corticosteroid, which is an orally active glucocorticoid receptor activator with anti-inflammatory activity. Flunisolide can induce eosinophil apoptosis, and is used for the research of asthma or rhinitis, and inflammation .

HY-B1121A

Flunisolide hemihydrate	Glucocorticoid Receptor Apoptosis	Inflammation/Immunology Endocrinology
Flunisolide hemihydrate is a corticosteroid, which is an orally active glucocorticoid receptor activator with anti-inflammatory activity. Flunisolide hemihydrate can induce eosinophil apoptosis, and is used for the research of asthma or rhinitis, and inflammation .

HY-19969

YM-90709 1 Publications Verification	Interleukin Related	Inflammation/Immunology
YM-90709 is a novel IL-5 inhibitor which selectively blocks the binding of IL-5 to the IL-5 receptor (IL-5R).YM-90709 potently inhibits the binding of [ ¹²⁵I]-IL-5 to IL-5R on human peripheral eosinophils and eosinophilic HL-60 clone 15 cells with IC₅₀ values of 1.0 and 0.57 μM .

HY-14277A

Levocabastine hydrochloride R 50547 hydrochloride	Histamine Receptor Neurotensin Receptor Integrin	Inflammation/Immunology
Levocabastine (R 50547) hydrochloride is a potent and selective histamine H1-receptor antagonist. Levocabastine hydrochloride is also a selective, high affinity neurotensin receptor subtype 2 (NTR2) antagonist, with a K_i of 17 nM for mNTR2. Levocabastine hydrochloride can act as a VLA-4 antagonist, interferes with conjunctival eosinophil infiltration in allergic conjunctivitis (AC) .

HY-14277

Levocabastine R 50547	Histamine Receptor Neurotensin Receptor Integrin	Inflammation/Immunology
Levocabastine (R 50547) is a potent and selective histamine H1-receptor antagonist. Levocabastine hydrochloride is also a selective, high affinity neurotensin receptor subtype 2 (NTR2) antagonist, with a K_i of 17 nM for mNTR2. Levocabastine can act as a VLA-4 antagonist, interferes with conjunctival eosinophil infiltration in allergic conjunctivitis (AC) .

HY-103158

BW B70C	Lipoxygenase	Others
BW B70C is a potent, selective and orally activearachidonic acid 5-lipoxygenase inhibitor. BW B70C inhibits both acute and allergic bronchoconstriction and late-phase eosinophil accumulation subsequent to allergen inhalation in guinea-pigs. BW B70C prevents leukotriene C4 synthesis and reduces leucocyte migration to the airways lumen as well as albumin microvascular leakage. BW B70C has the potential for the research of anti-asthma agent .

HY-P99371

Lirentelimab AK002; Anti-Siglec-8 Reference Antibody (lirentelimab)	Apoptosis	Inflammation/Immunology
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .

HY-P9945

Mepolizumab SB 240563	Interleukin Related	Cardiovascular Disease Inflammation/Immunology
Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .

HY-123532

JNJ10191584 VUF6002	Histamine Receptor	Neurological Disease
JNJ10191584 (VUF6002) is an orally active and selective histamine H₄ receptor antagonist with a K_i value of 26 nM. JNJ10191584 shows 540-fold selectivity to H₄ receptor over H₃ receptor with a K_i value of 14.1 μM. JNJ10191584 inhibits chemotaxis of eosinophils and mast cells with IC₅₀ values of 530 nM and 138 nM, respectively .

HY-P9945A

Mepolizumab (anti-IL5)	Interleukin Related	Inflammation/Immunology
Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .

HY-107558

JNJ10191584 maleate VUF6002 maleate	Histamine Receptor	Neurological Disease
JNJ10191584 (VUF6002) maleate (compound 40) is an orally active and selective histamine H₄ receptor antagonist with a K_i value of 26 nM. JNJ10191584 maleate shows 540-fold selectivity to H₄ receptor over the H₃ receptor with a K_i value of 14.1 μM. JNJ10191584 maleate inhibits chemotaxis of eosinophils and mast cells with IC₅₀ values of 530 nM and 138 nM, respectively .

HY-12887

Piclamilast RP 73401; RPR 73401	Phosphodiesterase (PDE)	Inflammation/Immunology Cancer
Piclamilast (RP 73401) is a phosphodiesterase 4 (PDE4) inhibitor, with IC₅₀ values of 16 nM and 2 nM in pig aorta and eosinophil soluble, respectively .

HY-B0629

Mometasone	Glucocorticoid Receptor	Metabolic Disease
Mometasone is an inhaled glucocorticoid. Mometasone can be used in mild asthma with a low sputum eosinophil level. Mometasone has the potential for the research of chronic hand eczema and rhinosinusitis .

HY-17042

Cetirizine 2 Publications Verification	Histamine Receptor	Inflammation/Immunology Endocrinology
Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .

HY-17042A

Cetirizine dihydrochloride 2 Publications Verification P071	Histamine Receptor	Inflammation/Immunology Endocrinology
Cetirizine dihydrochloride, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine dihydrochloride marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .

HY-112549

5-oxo-ETE 5-KETE	Others	Cardiovascular Disease Inflammation/Immunology Cancer
5-oxo-ETE is a potent chemoattractant for eosinophils. 5-oxo-ETE inhibits selenium-induced apoptosis in prostate cancer cells. 5-oxo-ETE can be used in research into asthma, allergic diseases, cancer and cardiovascular disease .

HY-100660A

Cetirizine Impurity B dihydrochloride	Drug Metabolite	Others
Cetirizine Impurity B dihydrochloride is an impurity of Cetirizine dihydrochloride. Cetirizine, a second-generation antihistamine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .

HY-100661

Cetirizine Impurity D	Histamine Receptor	Inflammation/Immunology Endocrinology
Cetirizine Impurity D is an impurity of Cetirizine. Cetirizine, a second-generation antihistamine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .

HY-153991

STAT6-IN-2	STAT	Inflammation/Immunology
STAT6-IN-2 (Comp R-84) is an inhibitor of STAT6. STAT6-IN-2 inhibits the secretion of chemokine eliciting eosinophil infiltration eotaxin-3. STAT6-IN-2 can be used for immune disease research .

HY-17042AS

Cetirizine-d4 dihydrochloride	Isotope-Labeled Compounds Histamine Receptor	Inflammation/Immunology
Cetirizine-d₄ (dihydrochloride) is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].

HY-17042AS1

Cetirizine-d8 dihydrochloride	Isotope-Labeled Compounds Histamine Receptor	Inflammation/Immunology
Cetirizine-d₈ (dihydrochloride) is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].

HY-17042S

Cetirizine-d4	Histamine Receptor	Inflammation/Immunology
Cetirizine-d₄ is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].

HY-P9923

Benralizumab MEDI-563; BIW-8405	Interleukin Related Apoptosis	Inflammation/Immunology Cancer
Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma .

HY-17042S1

Cetirizine-d8	Histamine Receptor	Inflammation/Immunology
Cetirizine-d₈ is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].

HY-120940

AZ13705339	PAK	Cancer
AZ13705339 is a highly potent and selective PAK1 inhibitor with IC₅₀s of 0.33 nM and 59 nM for PAK1 and pPAK1, respectively. AZ13705339 has binding affinities to PAK1 and PAK2, with K_ds of 0.28 nM and 0.32 nM, respectively. AZ13705339 can be used in the research of cancers .

HY-120940A

AZ13705339 hemihydrate	PAK	Cancer
AZ13705339 hemihydrate is a highly potent and selective PAK1 inhibitor with IC₅₀s of 0.33 nM and 59 nM for PAK1 and pPAK1, respectively. AZ13705339 hemihydrate has binding affinities to PAK1 and PAK2, with K_ds of 0.28 nM and 0.32 nM, respectively. AZ13705339 hemihydrate can be used in the research of cancers .

HY-11067

WHI-P97 2 Publications Verification	JAK	Inflammation/Immunology
WHI-P97 is a potent and selective JAK-3 inhibitor. WHI-P97 is effective in preventing the development allergic asthma in vivo .

HY-13315

Montelukast sodium Maximum Cited Publications 7 Publications Verification MK0476	Leukotriene Receptor	Inflammation/Immunology
Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research .

HY-13315A

Montelukast Maximum Cited Publications 7 Publications Verification MK0476 free base	Leukotriene Receptor	Inflammation/Immunology
Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .

HY-15131

PNRI-299	Interleukin Related	Inflammation/Immunology
PNRI-299 is a selective AP-1 transcription inhibitor with an IC₅₀ of 20 uM. PNRI-299 is a selective APE/Ref-1 inhibitor. PNRI-299 has no effect on NF-κB transcription or thioredoxin (up to 200 uM). PNRI-299 significantly reduces airway eosinophil infiltration, mucus hypersecretion, edema, and IL-4 levels in a mouse asthma model .

HY-116953

Lipoxin B4 LXB4	Endogenous Metabolite	Inflammation/Immunology
Lipoxin B4 (LXB4) is a structurally distinct product of arachidonic acid metabolism. Lipoxin B4 reduces leukocyte infiltration and mucus secretion in the nasal mucosa and decreases mast cell and eosinophil degranulation in the upper airway. Lipoxin B4 decreases airway inflammation, mucus metaplasia and hyper- responsiveness in the lower airway. Lipoxin B4 shows mucosal protective actions and has the potential for the research of allergic inflammation in the upper and lower airways .

HY-134772

AS1810722	STAT Cytochrome P450	Inflammation/Immunology
AS1810722 is an orally active and potent STAT6 inhibitor with an IC₅₀ of 1.9 nM. AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research .

HY-105999B

APC 366 TFA

Others Others

APC 366 (TFA) is an irreversible mast cell tryptase inhibitor. APC 366 (TFA) can be used for the research of allergic diseases .

APC 366 TFA	Others	Others
APC 366 (TFA) is an irreversible mast cell tryptase inhibitor. APC 366 (TFA) can be used for the research of allergic diseases .

HY-106837

Israpafant Y 24180	Platelet-activating Factor Receptor (PAFR)	Inflammation/Immunology
Israpafant (Y-24180) is a potent, selective and long-acting platelet activation factor (PAF) receptor antagonist with IC₅₀s of 0.84 nM and 3.84 nM against PAF-induced human and rabbit platelet aggregation, respectively. Israpafant stimulates both extracellular Ca ²⁺ influx and intracellular Ca ²⁺ release in prostate cancer cells. Israpafant suppresses the allergic cutaneous reactions including eosinophilia, cytokine production, edema and erythema in mice .

HY-13315B

Montelukast dicyclohexylamine MK0476 dicyclohexylamine	Leukotriene Receptor	Inflammation/Immunology
Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research .

HY-15342

Timapiprant 3 Publications Verification OC000459	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
Timapiprant (OC000459) is a potent, selective, and orally active D prostanoid receptor 2 (DP₂, also known as CRTH2) antagonist. Timapiprant (OC000459) potently displaces [ ³H] PGD2 from human recombinant DP₂ (K_i=13 nM), rat recombinant DP₂ (K_i=3 nM), and human native DP₂ (K_i=4 nM). Timapiprant (OC000459) inhibits mast cell activation of Th2 lymphocytes and eosinophils .

HY-15342A

Timapiprant sodium 3 Publications Verification OC000459 sodium	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
Timapiprant sodium (OC000459 sodium) is a potent, selective, and orally active D prostanoid receptor 2 (DP₂, also known as CRTH2) antagonist. Timapiprant sodium (OC000459 sodium) potently displaces [ ³H] PGD2 from human recombinant DP₂ (K_i=13 nM), rat recombinant DP₂ (K_i=3 nM), and human native DP₂ (K_i=4 nM). Timapiprant sodium (OC000459 sodium) inhibits mast cell activation of Th2 lymphocytes and eosinophils .

HY-13315R

Montelukast sodium (Standard) MK0476 (Standard)	Leukotriene Receptor	Inflammation/Immunology
Montelukast (sodium) (Standard) is the analytical standard of Montelukast (sodium). This product is intended for research and analytical applications. Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research .

HY-P9923A

Benralizumab (anti-IL5RA ) MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )	Interleukin Related	Inflammation/Immunology
Benralizumab (anti-IL5RA ) (MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma study .

HY-B1639

Enoximone	Phosphodiesterase (PDE)	Cardiovascular Disease Inflammation/Immunology
Enoximone is an inotropic vasodilating agent and a selective and orally active phosphodiesterase III (PDE3) inhibitor with an IC₅₀ of 5.9 μM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE. Enoximone also exhibits PDE4 inhibitory effect with an IC₅₀ of 21.1 μM for myocardial PDE4A. Enoximone has the potential for congestive heart failure research and has bronchodilatory, antiasthma and anti-inflammatory effects .

HY-110261

GS143	IKK E1/E2/E3 Enzyme NF-κB	Inflammation/Immunology
GS143 is a selective IκBα ubiquitination inhibitor with an IC₅₀ of 5.2 μM for SCF ^βTrCP1-mediated IκBα ubiquitylation. GS143 suppresses NF-κB activation and transcription of target genes and does not inhibit proteasome activity. GS143 has anti-asthma effect .

HY-B0809

Theophylline 5+ Cited Publications 1,3-Dimethylxanthine; Theo-24	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite	Cancer
Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-B0809B

Theophylline sodium acetate 1,3-Dimethylxanthine sodium acetate; Theo-24 sodium acetate	Endogenous Metabolite Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor	Cancer
Theophylline (1,3-Dimethylxanthine) sodium acetate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) sodium acetate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) sodium acetate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) sodium acetate induces apoptosis. Theophylline (1,3-Dimethylxanthine) sodium acetate can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

Cat. No.	Product Name	Target	Research Area